Skip to main content
BCRX
NASDAQ Life Sciences

BioCryst Increases Wholesale Acquisition Cost for Key Drug ORLADEYO® by 9%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$7.62
Mkt Cap
$1.606B
52W Low
$6
52W High
$11.31
52W Position info
27% above low
Off High info
33% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

BCRX sits 27% above its 52-week low of $6.

Summary

BioCryst Pharmaceuticals has raised the wholesale acquisition cost for its HAE drug, ORLADEYO®, by approximately 9%, effective January 9, 2026, which is expected to boost future revenue.


Key Events · Product Development and Regulatory · BCRX

  • ORLADEYO® Price Increase

    BioCryst Pharmaceuticals has increased the wholesale acquisition cost (WAC) for its drug ORLADEYO® from $44,484.33 to $48,487.92 per 28-day pack in the U.S.

  • Significant Revenue Impact

    The price adjustment represents an approximate 9% increase, which is expected to positively impact the company's future revenue and gross profit for this key product.

  • Immediate Effect

    The new pricing for ORLADEYO® is effective as of January 9, 2026.


Analysis · BCRX · Life Sciences

BioCryst Pharmaceuticals announced a 9% increase in the wholesale acquisition cost (WAC) for its hereditary angioedema (HAE) drug, ORLADEYO®. This price adjustment, effective immediately, is expected to positively impact the company's revenue and gross profit margins. For a commercial-stage biopharmaceutical company, a direct price increase on a flagship product can significantly enhance financial performance and accelerate the path to profitability, demonstrating strong pricing power for a specialized treatment.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BCRX was trading at $7.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $6.00 to $11.31. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BCRX - Latest Insights

BCRX
Nov 04, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.24
Real-time Price: $7.30 info
Change: -$0.940 (-11%) info
Market Cap: $1.878B info
BCRX
Nov 04, 2026, 7:03 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.66
Real-time Price: $7.30 info
Change: -$1.36 (-16%) info
Market Cap: $1.878B info
BCRX
Nov 04, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $8.52
Real-time Price: $7.30 info
Change: -$1.22 (-14%) info
Market Cap: $1.878B info
BCRX
Oct 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $8.02
Real-time Price: $7.30 info
Change: -$0.7185 (-9%) info
Market Cap: $1.878B info
BCRX
Aug 25, 2026, 7:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $9.65
Real-time Price: $7.30 info
Change: -$2.35 (-24%) info
Market Cap: $1.878B info